Vera Therapeutics, Inc. — Director's Dealing 2021

May 14, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Vera Therapeutics, Inc. (VERA)
CIK: 0001831828
Period of Report: 2021-05-13

Reporting Person: Cheng Andrew (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series C Preferred Stock	$		Class A Common Stock (17488)		Indirect
Stock Option (right to buy)	$4.4031	2027-08-15	Class A Common Stock (3452)		Direct
Stock Option (right to buy)	$2.3174	2030-01-15	Class A Common Stock (4315)		Direct
Stock Option (right to buy)	$2.8968	2030-12-15	Class A Common Stock (61276)		Direct

Footnotes

F1: The Series C Preferred Stock is convertible into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and has no expiration date. Upon filing of the Issuer's Restated Certificate of Incorporation in connection with the Issuer's initial public offering, all shares of Series C Preferred Stock will be converted into shares of Class A Common Stock of the Issuer.

F2: The shares are held of record by Andrew K. Cheng, as Trustee of the Andrew Cheng 2010 Trust UA 10-26-2010.

F3: 1/48 of the shares subject to the option vested on July 8, 2017, and 1/48 of the shares vest monthly thereafter.

F4: 1/36 of the shares subject to the option vested on February 10, 2020, and 1/36 of the shares vest monthly thereafter.

F5: 1/36 of the shares subject to the option vested on January 16, 2021, and 1/36 of the shares vest monthly thereafter.